type 2 diabetes
Western Sydney Diabetes adopts the mobile solution to automate patient engagement.
The study will focus on Type 2 diabetes patients.
The FootSense monitoring device spots changes in temperatures between a person's feet which may indicate complications.
The study was conducted by Omada and Evidation Health and included 195 participants.
Members in 27 states and Washington D.C. are eligible to receive the Level2 chronic care model at no additional cost.
Healthcare providers use a web interface to prescribe an initial dose "and BlueStar does the rest," according to Welldoc's chief medical officer.
HbA1c values also declined across a sample of program participants, many of whom said they were unfamiliar with the diabetes management tools prior to enrollment.
The tool considers vascular changes and individual risk data to make its predictions.
Reactions to the news are mixed, with some experts saying the test is unlikely to make much of a difference.
The d-Nav Insulin Guidance Service was also the focus of a multi-center, randomized control trial published last week in the Lancet.